

## Supporting Online Material

### Doc2b is a High Affinity Ca<sup>2+</sup> Sensor for Spontaneous Neurotransmitter Release

Alexander J. Groffen<sup>1,8,\*</sup>, Sascha Martens<sup>2,3,8,\*</sup>, Rocío Díez Arazola<sup>1</sup>, L. Niels Cornelisse<sup>1</sup>, Natalia Lozovaya<sup>1,4</sup>, Arthur P. H. de Jong<sup>1</sup>, Natalia A. Goriounova<sup>1,4</sup>, Ron L. P. Habets<sup>5</sup>, Yoshimi Takai<sup>6</sup>, J. Gerard Borst<sup>5</sup>, Nils Brose<sup>7</sup>, Harvey T. McMahon<sup>2,8</sup> and Matthijs Verhage<sup>1,8</sup>

### MATERIALS AND METHODS

#### Antibodies

To cross-absorb a previously described antiserum pAb13.2 raised against amino acids 22-116 of rat Doc2b (*S1*), a 2-ml column of cyanogen bromide-activated Sepharose beads conjugated to total brain lysate obtained from adult *Doc2a-b* double knockout mice. Fraction 5 of the flow through stained endogenous Doc2a and -b with no remaining signal of each protein in single and double-knockout mice. The dilution in phosphate-buffered saline was 1:100 or 1:500 for cytochemistry and blotting. Munc18-1 (pAb 2701, 1:2500) was home-made and validated against brain lysate from Munc18 null mice. Antibodies against synaptobrevin-2 (mAb 69.1, 1:2000 for cytochemistry or 1:5000 for blotting), munc13-1 (mAb 266B1, 1:1000), rab3 (mAb 42.1, 1:2000),  $\alpha/\beta$ -SNAP (mAb 77.2, 1:2000), syntaxin-1 (mAb HPC-1, 1:5000) and  $\alpha$ -tubulin (mAb 3A2, 1:5000) were from Synaptic Systems. Anti-SNAP25 (mAb SM181, 1:5000) was from Sternberger. Anti-MAP2 (chicken pAb ab5392, 1:20000) was from Abcam. Polyclonals against synaptotagmin-1 (pAb W855), -2 (I735), and -12 were a kind gift from Prof. T. Südhof and Dr. A. Maximov (*S2*). Goat-anti-mouse-Alexa488, goat-anti-rabbit-Alexa546 and goat-anti-chicken-Alexa647 (all 1:1000) were from Invitrogen. Western blot signals were produced by enhanced chemifluorescence, digitized with the FLA-5000 imaging system and quantified with AIDA imager analyzer software (Raytest).

#### Generation of knock-out mice

Animals were housed and bred according to institutional, Dutch, and US governmental guidelines. To generate Doc2b knock-out mice, a 16 kb genomic fragment was obtained from a  $\lambda$ ZAP 129/SvJ mouse genomic library (Stratagene) and used to construct a gene replacement vector designed to replace the *MluI-SalI* fragment with the *Doc2b* promoter and exon 1 by a floxed neomycin gene oriented in the antisense direction. The targeting vector was linearized with *SpeI* and electroporated into the mouse embryonic stem cell line E14.1, originating from the inbred strain 129P2/OlaHsd. Clones resistant to 450  $\mu$ g/ml G418 (Invitrogen) were isolated and tested for homologous recombination by PCR amplification and Southern blotting. Correctly targeted ES cells were injected into blastocysts and implanted in pseudopregnant females. Chimeric males were mated to C57BL/6 inbred females and heterozygous F1 offspring was backcrossed for more than 10 generations to C57BL/6 to ensure a homogenous genetic background. To exclude expression of the remaining exons in the targeted allele, RT-PCR amplification was performed with primers mav221 (caatgattcatcggtg) and mav204 (tgagaaagcccagggtg). Since the *Doc2b* null allele lacks exon 1, in situ hybridization was performed with a probe that hybridizes with exons 2-9 (nucleotides 512-1378 of the mRNA) as described previously (*S3*). *Doc2a/b* double knock-out mice were obtained by breeding with previously established *Doc2a* null mice (*S4*).

### **Autapse electrophysiology**

To prepare autapses, neurons were dissociated from hippocampi at embryonal stage E18 and plated on glial microislands (S5). Whole-cell recordings were performed at room temperature between 14 and 18 days in vitro. The intracellular solution was free of EGTA; it contained 125 mM K<sup>+</sup>-gluconic acid, 10 mM NaCl, 4.6 mM MgCl<sub>2</sub>, 4 mM K<sub>2</sub>-ATP, 15 mM creatine phosphate, 10 U/ml phosphocreatine kinase (pH=7.30, 300 mOsmol). The external medium contained 140 mM NaCl, 2.4 mM KCl, 4 mM CaCl<sub>2</sub>, 4 mM MgCl<sub>2</sub>, 10 mM glucose and 10 mM HEPES (pH 7.30, 300 mOsmol). Clampfit v9.2 was used for offline analysis of evoked EPSCs. Miniature EPSCs were detected using Mini Analysis v6.0.3 (Synaptosoft Inc) using a threshold amplitude of 10 pA. To calculate synchronous and asynchronous components of the EPSC charge as described (S6), a home-made routine was written in the MATLAB<sup>®</sup> environment (MathWorks).

For overexpression of full length rat Doc2b neurons were infected 8-15 h prior to analysis with Semliki particles encoding full length rat Doc2b and GFP, separated by an internal ribosome entry site. To control for effects caused by the Semliki infection we used particles encoding GFP alone. Recordings and analysis were performed while the identity of experimental groups was unknown to the experimenter. To monitor the expression and localization of overexpressed Doc2b, cells were fixed 12 h post infection with 4 % paraformaldehyde, stained as indicated above (see antibodies) and analyzed on a LSM510 confocal microscope (Zeiss).

To test the influence of EGTA and BAPTA on spontaneous release, spontaneous events were recorded first in naïve cells during 1 min, followed by a EPSC recording after stimulation. Cells were then incubated for 15 minutes in presence of 20 μM of AM-EGTA or AM-BAPTA (Invitrogen) in the bath solution. Successful BAPTA loading was confirmed by the inhibition of EPSC amplitude using 1 min stimulation intervals to avoid activity-induced artifacts.

### **mEPSC frequency in primary network cultures**

Hippocampal neurons from Doc2a/b double knockout mice were prepared as previously described (S7) except that the neurons were plated at 50K per 12-well on a confluent layer of glia. The cells were infected with lentiviral vectors encoding GFP, Doc2b<sup>WT</sup>, Doc2b<sup>4A</sup> or Doc2b<sup>D218,220N</sup> on DIV2. The infection efficiency was >90% for all constructs as confirmed by immunocytochemistry. For whole-cell recordings at DIV10-17 the neurons were analyzed with the same internal and external media as in autapses, except that the bath contained 1 mM Mg<sup>2+</sup>, 1 μM tetrodotoxin to block Na<sup>+</sup> currents (Ascent) and 20 μM gabazine to block GABA<sub>A</sub> receptor mediated currents (Sigma). The Ca<sup>2+</sup> concentration was varied from 0.2 to 1, 2, 5, 10 and then back to 0.2 mM by superfusion. mEPSC frequencies were quantitated as above; cells that never reached frequencies >0.2 Hz even at 10 mM Ca<sup>2+</sup> or with frequencies >12 Hz in 0.2 mM Ca<sup>2+</sup> were excluded from analysis (3 cells of 73 in total). The mEPSC frequency during the first and second measurement in 0.2 mM Ca<sup>2+</sup> did not deviate substantially, suggesting that the treatment did not compromise cell viability. The experimenters were blind to the expressed constructs during the recordings and analysis.

### **Whole-cell recordings in cerebellar Purkinje cells**

Spontaneous GABAergic input to Purkinje cells was measured in acute slices (S8). The extracellular medium contained 125 mM NaCl, 3 mM KCl, 1.2 mM NaH<sub>2</sub>PO<sub>4</sub>, 26 mM NaHCO<sub>3</sub>, 10 mM glucose, 1 mM Mg<sup>2+</sup> and 2 mM Ca<sup>2+</sup>. Spontaneous events were recorded in presence of tetrodotoxin and DNQX to block AMPA receptors. To verify that these conditions effectively blocked Purkinje cell firing, we confirmed that Ca<sup>2+</sup>-spikes and NMDA currents were absent. The intracellular solution contained 141 mM CsCl, 2 mM MgATP, 10

mM tetraethyl ammonium and 10 mM HEPES (pH 7.3) for voltage clamp recordings at age P6-P7, or 130 mM K-gluconate, 10 mM Na-gluconate, 4 mM NaCl, 4 mM MgATP, 0.3 mM NaGTP, 4 mM phosphocreatine and 10 mM HEPES (pH 7.3) for current clamp recordings at age P17-P18. Recordings and analysis were performed while the identity of experimental groups was unknown to the experimenter.

### **Calyx of Held electrophysiology**

Acute slices were prepared as described (S9). In brief, 8- to 10-day old pups were obtained from a mating between *Doc2a*<sup>+/-</sup>, *Doc2b*<sup>+/-</sup> and *Doc2a*<sup>-/-</sup>, *Doc2b*<sup>-/-</sup> mice. The number of mice investigated was: control (*Doc2a*<sup>+/-</sup> and *Doc2b*<sup>+/-</sup>; N=4), *Doc2a*-deficient (*Doc2a*<sup>-/-</sup> and *Doc2b*<sup>+/-</sup>; N=5), *Doc2b*-deficient (*Doc2a*<sup>+/-</sup> and *Doc2b*<sup>-/-</sup>; N=3), and DKO (*Doc2a*<sup>-/-</sup> and *Doc2b*<sup>-/-</sup>; N=6). Principal cells in the medial nucleus of the trapezoid body were selected for postsynaptic action potential firing upon stimulation of the axons originating from the cochlear nucleus. Whole-cell voltage clamp recordings were made with an Axopatch 200B amplifier (Molecular Devices, Union City, CA, USA) at a holding potential of -80 mV. Potentials were corrected for a -11 mV junction potential. Series resistance did not exceed 15 MOhm and was compensated for at least 90%. Signals were low-pass filtered at 2 kHz and digitized at 20–50 kHz with a Digidata 1320A (Molecular Devices). Miniature EPSCs were detected in Clampfit 9 with a template based search method (match threshold = 4). This threshold defines how well the mEPSC should match the rise time and decay time of a predefined template. In some experiments kynurenic acid (2mM, Tocris, Bristol, UK) was washed in to prevent post-synaptic receptor saturation and desensitization. Recovery from depression was measured with two 100 Hz trains with known interval (in kynurenic acid). All recordings and analysis were performed blind to the post-hoc determined genotype.

### **Statistical analyses**

Because the spontaneous release frequency is not normally distributed as indicated by a D'Agostino-Pearson normality test ( $p < 0.0001$ ), we applied the nonparametric Mann-Whitney test for independent samples. The spontaneous release frequencies before and after loading of a Ca<sup>2+</sup> chelator in the same cell were compared by a Wilcoxon rank sum test for paired samples. All P-values represent two-tailed probabilities.

### **Protein expression and purification**

All synaptotagmin-1, *Doc2a* and *Doc2b* fragments were expressed as glutathione-S-transferase (GST) fusion proteins from pGEX4T2 or pGEX4T1. The C2AB domain constructs comprised amino acids 96-421 of rat synaptotagmin-1 (NP\_001028852), amino acids 88-400 of rat *Doc2a* (NP\_075226) and amino acids 125-412 of rat *Doc2b* (NP\_112404). The C2A domain comprised amino acids 125-255 of rat *Doc2b* and the C2B domain comprised amino acids 265-412 of rat *Doc2b*. Mutations were introduced according to the Stratagene QuikChange protocol.

BL21(DE3) pLysS cells (Stratagene) were used for expression of the synaptotagmin-1, *Doc2a* and *Doc2b* C2A, C2B and C2AB domain fragments. Cells were grown at 37°C until 0.3 OD<sub>600</sub>, induced with 40 μM Isopropyl β-thiogalactopyranoside (IPTG) and grown for 14-16 h at 18°C. Cells were harvested and resuspended in 50 mM HEPES pH 7.5, 300 mM NaCl, 4 mM dithiothreitol (DTT), 2 mM MgCl<sub>2</sub>, DNaseI, RNaseA and lysed by freeze thawing. The lysate was centrifuged for 45 min at 125,000 g, 4°C and the supernatant was incubated with 1 ml of glutathione beads (GE healthcare) per 1 l of culture for 1-2 h. Beads were washed 7 times with 50 mM HEPES pH 7.5, 300 mM NaCl, 4 mM DTT followed by two 15 min washes with 50 mM HEPES pH 7.5, 700 mM NaCl, 4 mM DTT, 2 mM MgCl<sub>2</sub>, DNaseI, RNaseA. The protein was cleaved off the beads with thrombin by over night incubation at

16°C. The supernatant was concentrated and the protein was further purified by gelfiltration in 50 mM HEPES pH 7.5, 150 mM NaCl, 4 mM DTT using a HiLoad 16/60 Superdex 75 column (Pharmacia Biotech). For pull downs the GST-fusion proteins were purified as described above except that the protein was eluted from the glutathione beads with 20 mM glutathione and subsequently purified by gelfiltration in 50 mM HEPES pH 7.5, 150 mM NaCl, 4 mM DTT using a HiLoad 16/60 Superdex 200 column (Pharmacia Biotech). The proteins were shock frozen and stored at -80°C. Possible protein and RNA contamination was checked by SDS gel electrophoresis and UV spectroscopy, respectively.

Rat full length SNAP-25 (NP\_112253) and full length syntaxin-1 (NP\_446240) were expressed as GST fusion proteins in BL21(DE3) pLysS cells (Stratagene). Cells were grown at 37°C until OD<sub>600</sub> of 0.9-1, induced with 500 µM IPTG and grown for 4 h at 37°C. Cells were harvested and resuspended in 50 mM Tris pH 8, 300 mM KCl, 10% glycerol, 5% Triton X-100, 5 mM DTT, 2 mM MgCl<sub>2</sub>, DNaseI, EDTA-free Complete protease inhibitors (Roche) and lysed by freeze thawing. The lysate was centrifuged for 45 min at 125,000g, 4°C and the supernatant was incubated with 1 ml of glutathione beads (GE Healthcare) per 1 l of culture for 1-2 h. Beads were washed 6x with 50 mM Tris pH 8, 300 mM KCl, 10% glycerol, 1% Triton X-100, 5 mM DTT, EDTA-free Complete protease inhibitors (Roche) and two 15 minute washes with 50 mM Tris pH 8, 700 mM KCl, 10% glycerol, 1% Triton X-100, 5 mM DTT. Subsequently the beads were washed with over 20 bead volumes of 50 mM Tris pH 8, 100 mM KCl, 10% glycerol 0.8% w/v n-octyl β-D-glucopyranoside (OGP), 5 mM DTT. SNAP-25 and syntaxin-1a were cleaved off the beads with thrombin over night at 16°C. Thrombin was then inactivated by the addition of 0.1 mM phenylmethylsulphonyl fluoride (PMSF) followed by 1 h incubation at room temperature. The supernatant was shock frozen and stored at -80°C. The functionality of SNAP25, syntaxin1 and synaptobrevin was monitored by SDS-resistant SNARE complex formation.

Rat full length synaptobrevin (NP\_036795) was expressed as GST fusion protein from pGEX4T1 in BL21(DE3) pLysS cells. Cells were grown at 37°C until OD<sub>600</sub> of 0.3, induced with 40 µM IPTG and grown for 14-16 h at 18°C. Cells were harvested and resuspended in 25 mM HEPES pH 7.5, 400 mM KCl, 1% Triton X-100, 2 mM MgCl<sub>2</sub>, 4 mM DTT, EDTA-free Complete protease inhibitors (Roche), 0.2 mM PMSF, DNaseI. Cells were lysed by freeze thawing and the lysate was centrifuged for 45 min at 125,000g, 4°C and the supernatant was incubated with 1 ml of glutathione beads (GE healthcare) per 1 l of culture for 1-2 h. Beads were washed 6x with 25 mM HEPES pH 7.5, 400 mM KCl, 1% Triton X-100, 4 mM DTT, EDTA-free Complete protease inhibitors (Roche) and two 15 minutes washes with 25 mM HEPES pH 7.5, 700 mM KCl, 5% Triton X-100, 4 mM DTT. Subsequently with 25 mM HEPES pH7.5, 100 mM KCl, 10% glycerol, 1% w/v OGP, 4 mM DTT. Synaptobrevin was cleaved off the beads with thrombin over night at 4°C. Thrombin was then inactivated by the addition of 0.1 mM PMSF followed by 1 h incubation at room temperature. The supernatant was shock frozen and stored at -80°C.

The SNARE domains of rat synaptobrevin (amino acids 1-96), rat syntaxin1A (amino acids 180-265), rat SNAP25 (amino acids 11-82 and 141-206) were expressed as GST fusion proteins from pGEX4T1 in BL21(DE3) pLysS cells (Stratagene). Cells were grown at 37°C until OD<sub>600</sub> of 0.3, induced with 40 µM IPTG and grown for 14-16 h at 18°C. Cells were harvested and resuspended in 50 mM HEPES pH 7.5, 300 mM NaCl, 4 mM DTT, 2 mM MgCl<sub>2</sub>, DNaseI and lysed by freeze thawing. The lysate was centrifuged for 45 min at 125,000g, 4°C and the supernatant was incubated with 1 ml of glutathione beads (GE healthcare) per 1 l of culture for 1-2 h. Beads were washed 7 times with 50 mM HEPES pH 7.5, 300 mM NaCl, 4 mM DTT followed by two 15 min washes with 50 mM HEPES pH 7.5, 1 M NaCl, 1% Tx100 followed by 4 washes with 50 mM HEPES pH 7.5, 300 mM NaCl, 4 mM DTT. The protein was cleaved off the beads with thrombin by over night incubation at

4°C. The supernatant was concentrated and the protein was further purified by gel filtration in 25 mM HEPES pH 7.5, 100 mM NaCl, 4 mM DTT using a HiLoad 16/60 Superdex 75 column (Pharmacia Biotech). For pull downs the GST-fusion proteins were purified as described above except that the protein was eluted from the glutathione beads with 20 mM glutathione and subsequently gel filtered. The SNARE domains were then mixed in a ratio of 1:1:1:1 and incubated on room temperature for 2 h. The SNARE complex was further purified by gel filtration in 25 mM HEPES pH 7.5, 100 mM NaCl, 4 mM DTT using a HiLoad 16/60 Superdex 75 column (Pharmacia Biotech) and finally concentrated, shock frozen and stored at -80°C.

For the co-expression of the synaptobrevin, SNAP25 and syntaxin1 SNARE domains the pOPC co-expression system was used. The synaptobrevin SNARE domain was first cloned into pOPTG to generate an N-terminal fusion protein. The SNARE domains of syntaxin1 and SNAP25 were cloned into pOPT. All SNARE domains were subsequently cloned into pOPC to generate the co-expression plasmid pOPC-SC. The pOPC-SC plasmid was transformed into BL21(DE3) pLysS cells (Stratagene) and the complex was purified as described for the isolated SNARE domains.

Possible protein and RNA contamination was checked by SDS gel electrophoresis and UV spectroscopy, respectively. The proteins are purified to crystallography standards.

### **Co-sedimentation assays**

Liposomes were prepared using either Folch lipids (fraction1, Sigma) or 2.5% PtdIns(4,5)P<sub>2</sub> (Avanti #840046), 10% cholesterol (Sigma), 27.5% PtdSer (Avanti #840032), 60% PtdChol (Avanti #840053) or 10% cholesterol (Sigma), 25% PtdSer (Avanti #840032), 65% PtdChol (Avanti #840053). Lipids were combined, dried under argon, desiccated for 2h and buffer was added to a final concentration of 1mg/ml liposomes. 0.5 mg/ml liposomes were incubated with 20 µg of the proteins indicated in the figures. Ca<sup>2+</sup> or EDTA (for the -Ca<sup>2+</sup> samples) were added to a final concentration of 1 mM. After 30 min at room temperature the liposomes were centrifuged at 165,000g for 10 min at room temperature. Equal amounts of the supernatants and pellets were loaded on 4-12% gradient gels (Invitrogen). To determine the Ca<sup>2+</sup> dose-dependence of phospholipid binding by the C2A domain, we used a previously described method (S10).

### **Liposome tubulation assay by negative stain electron microscopy**

Folch lipids (fraction 1, Sigma) were dried under argon, desiccated for 2 h and buffer was added to a final concentration of 1 mg/ml liposomes. 0.3 mg/ml Folch liposomes were incubated with 10 µM of the respective proteins in the presence of 1 mM EDTA or CaCl<sub>2</sub> for 1 h at room temperature and stained with 2% uranylacetate.

### **Pull down assays**

For the pull down assay shown in Fig. 4A 30 µg of the GST- Doc2b C2AB domain was bound to 50 µl glutathione beads equilibrated in wash buffer (25 mM HEPES pH 7.5, 100 mM NaCl, 4 mM DTT). The proteins were bound to beads by a 30 min incubation at 4°C. The beads were washed 2 times with wash buffer plus 1 mM EDTA or CaCl<sub>2</sub>, respectively. 30 µg of the purified SNARE complex was added followed by a 30 min incubation at 4°C. The beads were subsequently washed four times with wash buffer plus 1 mM EDTA or CaCl<sub>2</sub>. Beads were resuspended in 60 µl SDS sample buffer, incubated for 10 min at room temperature, briefly centrifuged and 25 µl of the supernatant was loaded on a 4-12% gradient gel.

For the experiment shown in Fig. 4B 30µg of the co-expressed and purified GST-SNARE complex was bound to 20 µl glutathione beads for 1h at 4°C. The beads were washed

and incubated with 17 $\mu$ g of Doc2b C2AB (1:0), 17 $\mu$ g of Doc2b C2AB and 17  $\mu$ g of synaptotagmin-1 C2AB (1:1), 17 $\mu$ g of Doc2b C2AB and 34  $\mu$ g of synaptotagmin-1 C2AB (1:2), 17 $\mu$ g of Doc2b C2AB and 85  $\mu$ g of synaptotagmin-1 C2AB (1:5), 17 $\mu$ g of Doc2b C2AB and 170  $\mu$ g of synaptotagmin-1 C2AB (1:10) in 50 mM HEPES pH 7.5, 100 mM NaCl, 4 mM DTT, 0.5 mM CaCl<sub>2</sub> for 1h at 4<sup>o</sup>C. Incubation was followed by 2 washes with 50 mM HEPES pH 7.5, 100 mM NaCl, 4 mM DTT, 0.5 mM CaCl<sub>2</sub>. Beads were resuspended in 50  $\mu$ l SDS sample buffer, incubated for 10' at room temperature, briefly centrifuged and 10  $\mu$ l of the supernatant was loaded on a 4-12% gradient gel.

For the pull down experiment shown in supplementary Fig. 7 30  $\mu$ g of the GST-SNARE complex (assembled using individually purified SNARE domains) was bound to 50  $\mu$ l glutathione beads equilibrated in wash buffer (25 mM HEPES pH 7.5, 100 mM NaCl, 4 mM DTT). The proteins were bound to beads by a 30 min incubation at 4<sup>o</sup>C. The beads were washed 2 times with wash buffer plus 1 mM EDTA or CaCl<sub>2</sub>, respectively. 30  $\mu$ g of the purified Doc2b C2AB domain and synaptotagmin-1 C2AB domain was added followed by a 30 min incubation at 4<sup>o</sup>C. The beads were subsequently washed four times with wash buffer plus 1 mM EDTA or CaCl<sub>2</sub>. Beads were resuspended in 60  $\mu$ l SDS sample buffer, incubated for 10 min at room temperature, briefly centrifuged and 25  $\mu$ l of the supernatant was loaded on a 4-12% gradient gel.

### **Reconstitution of membrane fusion**

The tSNARE and vSNARE liposomes were prepared by detergent assisted insertion into preformed liposomes as described previously (*S11*).

tSNARE liposomes: To create a 20 mM liposome suspension lipids stored in chloroform were mixed in the following ratio: 25% phosphatidylserine (PtdSer) (Avanti #840032), 10% cholesterol (Sigma), 65% phosphatidylcholine (PtdChol) (Avanti #840053). Lipids were dried under argon and desiccated for 2 h. Lipids were re-hydrated by the addition of 50 mM Tris pH 8, 150 mM NaCl, 2 mM DTT. Lipids were incubated in the buffer for 15 min at room temperature and subsequently sonicated gently. The liposomes were then passed 9 times through an 800 nm filter (Whatman). 10  $\mu$ l of the liposomes were then added to 90  $\mu$ l of an 11.1 $\mu$ M tSNARE complex solution and incubated for 15 min at room temperature. The detergent was then diluted below the critical micelle concentration by the addition of 100  $\mu$ l 50 mM Tris pH 8, 150 mM NaCl, 2 mM DTT. The liposomes were then dialyzed overnight against 2 l of 25 mM HEPES pH 7.5, 100 mM KCl, 5% glycerol, 2 mM DTT, 10 g BioBeads (BioRad) at 4<sup>o</sup>C to remove the detergent and spun at 10,000g for 5 min at room temperature to remove aggregates. The supernatant was used for experiments.

vSNARE liposomes: To create a 10 mM liposome suspension lipids stored in chloroform were mixed in the following ratio: 15% phosphatidylserine (PtdSer) (Avanti #840032), 10% cholesterol (Sigma), 72% phosphatidylcholine (PtdChol) (Avanti #840053), 1.5% N-(7-nitro-2-1,3-benzoxadiazol-4-yl)-1,2-dipalmitoyl phosphatidylethanolamine (Invitrogen) and 1.5% rhodamine-phosphatidylethanolamine (Invitrogen), dried under argon and desiccated for 2 h. Lipids were rehydrated by the addition of 50 mM Tris pH 8, 150 mM NaCl, 2 mM DTT. Lipids were incubated in the buffer for 15 min at room temperature and sonicated gently. The liposomes were then passed 9 times through a 800 nm filter (Whatman). 20  $\mu$ l of the liposomes were added to 80  $\mu$ l of a 50  $\mu$ M solution of synaptobrevin and incubated for 15 min at room temperature. The detergent was then diluted below the critical micelle concentration by the addition of 100  $\mu$ l 50 mM Tris pH 8, 150 mM NaCl, 2 mM DTT. The liposomes were then dialyzed overnight against 2 l of 25 mM HEPES pH 7.5, 100 mM KCl, 5% glycerol, 2 mM DTT, 10 g BioBeads (BioRad) overnight at 4<sup>o</sup>C to remove the detergent and spun at 10,000g for 5 min at room temperature to remove aggregates. The supernatant was used for experiments.

Assuming a 100% efficient reconstitution of the proteins a protein/lipid ratio of 1:50 would be achieved for the vSNARE liposomes and a ratio of 1:100 for the tSNARE liposomes. As judged by co-floitation assays we achieved a reconstitution efficiency of about 90% for the vSNARE liposomes and 80% for the tSNARE liposomes. The integrity of the reconstituted proteo-liposomes was controlled by negative stain EM and the size distribution (60-70nm) was analyzed by dynamic light scattering. In addition the orientation of the SNAREs in the liposome membrane was analyzed by incubation with Botulinum neurotoxin E or Tetanus toxin. As expected for random integration only 50% of SNAP-25 and synaptobrevin, respectively were cleaved. The purity of the SNAREs used for the fusion experiments was over 90% as judged by SDS-PAGE and Coomassie staining.

For the fusion experiments 75  $\mu$ l tSNARE liposomes were mixed with 25  $\mu$ l vSNARE liposomes. The synaptotagmin-1, Doc2a and Doc2b fragments were added at a final concentration of 7.5  $\mu$ M. The reactions were incubated on ice for 30 min before measurement.  $\text{Ca}^{2+}$  was added immediately before the measurement to final concentration of 500  $\mu$ M. Fusion was monitored by dequenching of NBD upon dilution of the NBD incorporated in the vSNARE vesicles with the tSNARE vesicles after fusion. The NBD was excited at 465 nm and emission was detected at 530 nm. After 20 min 10% Triton X-100 was added to a final concentration of 1% to determine the maximum fluorescence. The Triton X-100 used in this study quenches the NBD fluorescence to about 70% of its maximum value. The increase of fluorescence mediated by SNARE/Doc2b/ $\text{Ca}^{2+}$  is thus lower by a factor of 1.4.

In order to facilitate detection of the initial fusion reaction we added a volume of 10  $\mu$ l 5 mM  $\text{CaCl}_2$  or EDTA in reaction buffer to the warm fusion reaction in the quartz cuvette. The measurement was started immediately after addition of 10  $\mu$ l 5 mM  $\text{CaCl}_2$  or EDTA (Fig. 4D, G, H) or after addition of 10  $\mu$ l of EGTA buffered  $\text{Ca}^{2+}$ -solutions containing free  $\text{Ca}^{2+}$  concentrations of 0, 0.35, 0.6, 1.4, 39 and 1000  $\mu$ M, respectively. (Fig. 4F). In the experiment shown in Fig. 4e  $\text{CaCl}_2$  was added during the measurement.

In the experiment in which the soluble (amino acids 1-96) fragment of synaptobrevin2 was added (Fig. 4E) the protein was added to a final concentration of 2  $\mu$ M to pre-incubation reaction including v- and tSNARE liposomes and Doc2b C2AB.


### **Modelling of the Doc2b C2A and C2B domain structures**

For the modelling of the Doc2b C2A and C2B domain structures Swissmodel was used (<http://swissmodel.expasy.org>). The rat Doc2b C2A domain sequence (amino acids 125-255) was submitted and modelled onto the structure of the rabphilin3a C2A domain crystal structure (PDB code 2chd) (*S12*). The sequence identity between the Doc2b and rabphilin3A C2A domains is above 80%.

For the C2B domain the rat Doc2b C2B domain sequence (aa 265-412) was submitted and modelled onto the structure of the rabphilin3a C2B domain (PDB code 2cm5) (*S13*). The sequence identity between the Doc2b and rabphilin3a C2B domains is 76%. The illustrations were created using CCP4 Molecular Graphics (available at <http://www.ytbl.york.ac.uk/~ccp4mg/>). The alignments were created with ClustalX 2.02 (<ftp://ftp.ebi.ac.uk/pub/software/clustalw2>) and manually modified using Genedoc (<http://www.nrbsc.org/downloads/>).

FIGURES AND TABLES


Figure S1



**Fig. S1.** Generation of *Doc2b* knock-out mice. (A) The promoter and exon 1 encoding the N-terminal domain of mouse *Doc2b* were deleted by homologous recombination. (B-C) No detectable expression of the remaining exons was detected by RT-PCR (B) or in situ hybridization (C) of adult *Doc2b*<sup>-/-</sup> mouse brains whereas *Doc2b* expression was prominent in the CA1 field and dentate gyrus (DG) of the hippocampus and the Purkinje cell (PC) layer of the cerebellum in wild-type littermates. (D) The loss of *Doc2b* immunoreactivity was not accompanied by changes in the immunoreactivity of other proteins tested in total brain lysate. The bar graph shows quantitation where we made repetitions: *Doc2b* (n=4); *Doc2a* (4); *Munc13-1* (1); *Munc18-1* (4); *Rab3* (1);  $\alpha$ / $\beta$ -SNAP (3); SNAP25 (3); Synaptobrevin-2 (3); Synaptotagmin-1 (5); Synaptotagmin-2 (2); Synaptotagmin-12 (2); Syntaxin-1 (3);  $\alpha$ -Tubulin (1). Note that the remaining *Doc2b* immunoreactivity reflects aspecific background signal. (E) *Doc2b*<sup>-/-</sup> mice were viable and fertile and developed a body weight that did not differ significantly from their wildtype littermates (N=13, 15 and 10 respectively for wildtypes, heterozygotes and homozygous null mice). (F) *Doc2b*<sup>+/-</sup> (N=409) and *Doc2a*<sup>+/-</sup> mice (N=225) yielded offspring with the expected Mendelian genotype frequencies. (G) Double-knockout mice were also viable and reached adulthood with no detectable *Doc2a/b* reactivity in adult brain lysate. The remaining bands represent cross-reactivity of the antibody with other gene products (asterisks).




Figure S2




**Fig. S2.** Evoked and spontaneous release in hippocampal autapses from Doc2a/b-double knockout (DKO) mice. Data presented here are derived from the same experiments as Fig. 1. (**A, B**) Typical EPSC recordings during repetitive stimulation at 5 or 40 Hz. The synchronous and asynchronous components of the total charge were estimated as defined in the inset (*S6*). (**C**) The RRP size was estimated by back-extrapolation of the cumulative charge during 40 Hz trains. Typical example is from a DKO cell. (**D**) Mean RRP size  $\pm$  sem (number of observations is indicate between brackets). (**E**) Spontaneous release rates varied considerably between experiments. To exclude any confounding effects, we performed 9 different experiments in which simultaneously prepared cultures of WT and DKO cells were compared. Mean mEPSC frequencies  $\pm$  sem are given with numbers of observations between brackets. ‘Pooled data’ corresponds to all observations taken together. (**F**) Postsynaptic parameters describing the shape and size of spontaneous release events in DKO and control cells. (**G**) In cells loaded with BAPTA, the ability of BAPTA to absorb  $\text{Ca}^{2+}$  transients was confirmed by an almost complete inhibition of evoked EPSCs. (**H**) Under the conditions used, the frequency of spontaneous release reaches a steady state after 15 min incubation with AM-BAPTA.

**Figure S3**




**Fig. S3.** Acute expression of Doc2b in DKO neurons. To test if acute overexpression of Doc2b affects spontaneous release, DKO neurons grown on glial microislands were infected with Semliki particles encoding Doc2b. **(A)** Immunoreactivity was observed in all subcellular compartments including the soma (not shown), dendrites (d), axons (a) and synapses (arrowheads). Cells were counterstained for MAP2 to mark dendrites and synaptotagmin (Syt) or synaptobrevin-2 (Syb) to mark synaptic vesicles. **(B)** Amplitude and shape characteristics (10-90% rise time, halfwidth and decay time constant) of spontaneous EPSCs in DKO neurons rescued with Doc2b or GFP as a control.

**Figure S4**




**Fig. S4.** Neurotransmission at the calyx of Held synapse. **(A)** Whole-cell voltage clamp recordings at the calyx of Held synapse did not reveal significant differences in the frequency or amplitude of miniature events. **(B)** Evoked EPSC amplitude and shape were normal in all groups. **(C)** The size of the ready-releasable pool was normal as estimated by back-extrapolation of the cumulative EPSC during a 100 Hz train.

Figure S5




**Fig. S5.** Structural comparison of C2 domains of Doc2b and synaptotagmin-1. **(A)** Alignment of the C2A domain sequences of human rabphilin3A, rat Doc2b, rat Doc2a and rat synaptotagmin-1. The hydrophobic amino acids at the tip of the Ca<sup>2+</sup>-binding loops are highlighted in green and the positive amino acids in the insertion of the rabphilin3A, Doc2b and Doc2a C2A domains are highlighted in blue. For the structures of the synaptotagmin-1 and Doc2b C2A domains ribbons (left) and the electrostatic surface potentials (right) are shown. The synaptotagmin-1 C2A domain structure is derived from pdb code 1BYN (*S14*). The structure of the Doc2b C2A domain was modelled using the rabphilin3A C2A domain (2CHD) (*S12*) as template. The dark green residues represented as “spheres” in the synaptotagmin1 and Doc2b C2A domain structures correspond to the residues highlighted dark green in the alignment. The dark blue residues represented as spheres in the Doc2b C2A domain structure correspond to the dark blue residues in the alignment. **(B)** Alignment of the C2B domains of rat rabphilin3A, rat Doc2b, rat Doc2a and rat synaptotagmin-1 using the same color code as described for the C2A domains in (A). For the structures of the synaptotagmin-1 and Doc2b C2B domains ribbons (left) and the electrostatic surface potentials (right) are shown. The synaptotagmin-1 C2B domain structure is derived from pdb code 1UOW (*S15*). The structure of the Doc2b C2B domain was modelled using the rabphilin3A C2B domain, pdb 2CM5 (*S13*) as template. The dark blue residues represented as spheres in the Doc2b C2A domain structure correspond to the dark blue residues in the alignment.

**Figure S6**



**Fig. S6.** Identification of the Ca<sup>2+</sup>-independent membrane binding sites in the Doc2b C2A and C2B domains. Liposome co-sedimentation assay using liposomes of the indicated composition and the indicated Doc2b mutants to analyze the membrane-binding properties of the C2A and C2B domains of Doc2b. The control panel on the left (surrounded by a red box) is reproduced from Fig. 3. The Ca<sup>2+</sup>-independent binding of the C2A domain to PIP<sub>2</sub>-containing and Folch liposomes was surprising as this activity has not been described in the highly homologous C2A domain of synaptotagmin-1. In order to locate the Ca<sup>2+</sup>-independent PIP<sub>2</sub> binding site in Doc2b we aligned the C2A domain sequences of synaptotagmin-1, Doc2b and the closely related C2A domains of Doc2a and rabphilin3A. The alignment revealed a conspicuous insertion containing the sequence KKLK into the loop connecting beta-strand 7 and 8 (Fig. S5). The mutation K237E (generating the sequence KELK) almost completely abolished Ca<sup>2+</sup>-independent liposome binding. In the predicted C2 domain structure K237 is located on the opposite site of the Ca<sup>2+</sup> binding pocket, and may thus allow the Doc2b C2A domain to bind to two membranes simultaneously in the presence of Ca<sup>2+</sup> (Fig. S5). In order to locate the Ca<sup>2+</sup>-independent PIP<sub>2</sub> binding site in the C2B domain we mutated K319, located in a polybasic region which is present in many C2 domains including the C2B domain of synaptotagmin-1 (*S11*, *S16*). The K319E mutant C2B domain lost Ca<sup>2+</sup>-independent membrane binding indicating that this site is functionally conserved between synaptotagmin-1 and Doc2b. Consistent with K237 and K319 being involved in Ca<sup>2+</sup>-independent PIP<sub>2</sub> binding the double mutant Doc2b C2AB fragment almost entirely lost Ca<sup>2+</sup>-independent binding to Folch liposomes but retained Ca<sup>2+</sup>-dependent liposome binding (compare to Fig. 3).


**Figure S7**



**Fig. S7.** Pull down experiments using the SNARE complex as bait. 30  $\mu$ g of the SNARE complex assembled on GST-synaptobrevin (the SNARE domains of SNAP25 and syntaxin-1 did not harbor a N-terminal GST tag) were attached to beads and subsequently incubated with 30  $\mu$ g of the synaptotagmin C2AB domain, wild-type or mutant Doc2b C2AB domains for 30 minutes at 4°C in the absence (1 mM EDTA) or presence of 1 mM Ca<sup>2+</sup>. 30 % of the bound material was loaded on 4-12% gradient gels. The gels were stained with Coomassie (the arrows indicate the position of GST-syb: GST-synaptobrevin 1-96, GST-SC: GST-SNARE complex, Syt1: synaptotagmin-1 SC: SNARE complex).



## Figure S8



**Fig. S8.**  $\text{Ca}^{2+}$ -dependence of liposome co-sedimentation by wild type and mutant Doc2b C2AB. **(A)** Coomassie stained gels of the liposome co-sedimentation assays. The liposomes were composed of 70% PC, 20% PS and 10% cholesterol. At high  $\text{Ca}^{2+}$  concentrations (1 mM) the extent of liposome-binding by the 4A and D218, 220N mutants were decreased presumably because of unspecific masking of head group charges by the high concentration of divalent cations. **(B)** Liposome binding of K221Q mutant showing no decrease in the  $\text{Ca}^{2+}$ -dependent binding compared to WT protein (as in panel A) as might be predicted from a similar mutation in synaptotagmin-1 (R233Q) (*SI7*). AU: arbitrary units.

**Table S1**

Figure	Genotype	Expressed protein	[Ca <sup>2+</sup> ] <sub>jex</sub>	Frequency (Hz)	sem	n (cells)
Fig. 1	Control	none	4 mM	6.23	0.63	169
	DKO	none	4 mM	3.29	0.37	148
		GFP (Semliki)	4 mM	3.06	0.55	46
		Doc2b WT (Semliki)	4 mM	5.49	0.77	54
Fig. 2	Control	none	2 mM	0,71	0,07	28
	Doc2b (-/-)	none	2 mM	0,19	0,02	15
Fig. 5B	DKO	GFP (Lenti)	0.2 mM	1,21	0,15	16
			1 mM	1,69	0,29	21
			2 mM	1,94	0,32	21
			5 mM	4,63	0,61	21
			10 mM	4,68	0,88	20
		Doc2b WT (Lenti)	0.2 mM	2,31	1,12	10
			1 mM	3,84	1,72	10
			2 mM	5,17	2,86	10
			5 mM	8,59	3,46	10
			10 mM	12,94	4,12	9
		Doc2b D218,220N (Lenti)	0.2 mM	9,66	2,48	26
			1 mM	9,53	2,20	26
			2 mM	11,72	2,55	26
			5 mM	16,01	3,05	26
			10 mM	17,08	3,59	25
		Fig. 5C	Control	GFP (Lenti)	0.35 mM	0,62
1 mM	0,93				0,16	34
5 mM	1,09				0,45	14
10 mM	2,89				0,56	5
Doc2b WT (Lenti)	0.35 mM			1,03	0,29	36
	1 mM			1,30	0,40	16
	5 mM			1,81	0,50	17
	10 mM			8,95	1,85	9
Doc2b D218,220N (Lenti)	0.35 mM			2,70	0,54	34
	1 mM			3,11	0,74	33
	5 mM			3,87	0,80	20
	10 mM			9,20	3,59	7
Fig. 5D	DKO	Doc2b WT (Lenti)	0.2 mM	2,48	0,44	34
			1 mM	2,87	0,54	34
			2 mM	4,01	1,10	34
			5 mM	5,81	0,00	34
			10 mM	11,00	0,00	31
		Doc2b K237,319E (lenti)	0.2 mM	1,70	0,36	31
			1 mM	1,77	0,35	30
			2 mM	2,43	0,35	31
			5 mM	3,48	0,68	31
			10 mM	5,28	1,12	25

**Table S1.** Overview of spontaneous release frequencies measured in hippocampal autapses and Purkinje cells. Data from Fig. 1 (autapses), Fig. 2 (cerebellar Purkinje cells) and Fig. 5 (network cultures) are listed together with their experimental parameters, mean values, standard errors and cell numbers.

## REFERENCES

- S1. A. J. Groffen *et al.*, *J Biol Chem* **279**, 23740 (2004).
- S2. A. Maximov, O. H. Shin, X. Liu, T. C. Sudhof, *J Cell Biol* **176**, 113 (2007).
- S3. A. J. Groffen, L. Jacobsen, D. Schut, M. Verhage, *J Neurochem* **92**, 554 (2005).
- S4. G. Sakaguchi *et al.*, *The European journal of neuroscience* **11**, 4262 (1999).
- S5. K. D. Wierda, R. F. Toonen, H. de Wit, A. B. Brussaard, M. Verhage, *Neuron* **54**, 275 (2007).
- S6. Y. Otsu *et al.*, *J Neurosci* **24**, 420 (2004).
- S7. J. Xu, Z. P. Pang, O. H. Shin, T. C. Sudhof, *Nat Neurosci* **12**, 759 (2009).
- S8. A. Fisyunov, V. Tsintsadze, R. Min, N. Burnashev, N. Lozovaya, *J Neurophysiol* **96**, 1267 (2006).
- S9. R. L. Habets, J. G. Borst, *J Physiol* **564**, 173 (2005).
- S10. R. Friedrich *et al.*, *J Neurosci* **28**, 6794 (2008).
- S11. S. Martens, M. M. Kozlov, H. T. McMahon, *Science* **316**, 1205 (2007).
- S12. M. Biadene, P. Montaville, G. M. Sheldrick, S. Becker, *Acta Crystallogr D Biol Crystallogr* **62**, 793 (2006).
- S13. P. Montaville *et al.*, *J Biol Chem* **282**, 5015 (2007).
- S14. X. Shao, I. Fernandez, T. C. Sudhof, J. Rizo, *Biochemistry* **37**, 16106 (1998).
- S15. Y. Cheng *et al.*, *Protein Sci* **13**, 2665 (2004).
- S16. J. Bai, W. C. Tucker, E. R. Chapman, *Nat Struct Mol Biol* **11**, 36 (2004).
- S17. R. Fernandez-Chacon *et al.*, *Nature* **410**, 41 (2001).